Literature DB >> 23663742

An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice.

William L Holland1, Andrew C Adams, Joseph T Brozinick, Hai H Bui, Yukiko Miyauchi, Christine M Kusminski, Steven M Bauer, Mark Wade, Esha Singhal, Christine C Cheng, Katherine Volk, Ming-Shang Kuo, Ruth Gordillo, Alexei Kharitonenkov, Philipp E Scherer.   

Abstract

FGF21, a member of the fibroblast growth factor (FGF) superfamily, has recently emerged as a regulator of metabolism and energy utilization. However, the exact mechanism(s) whereby FGF21 mediates its actions have not been elucidated. There is considerable evidence that insulin resistance may arise from aberrant accumulation of intracellular lipids in insulin-responsive tissues due to lipotoxicity. In particular, the sphingolipid ceramide has been implicated in this process. Here, we show that FGF21 rapidly and robustly stimulates adiponectin secretion in rodents while diminishing accumulation of ceramides in obese animals. Importantly, adiponectin-knockout mice are refractory to changes in energy expenditure and ceramide-lowering effects evoked by FGF21 administration. Moreover, FGF21 lowers blood glucose levels and enhances insulin sensitivity in diabetic Lep(ob/ob) mice and diet-induced obese (DIO) mice only when adiponectin is functionally present. Collectively, these data suggest that FGF21 is a potent regulator of adiponectin secretion and that FGF21 critically depends on adiponectin to exert its glycemic and insulin sensitizing effects.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23663742      PMCID: PMC3667496          DOI: 10.1016/j.cmet.2013.03.019

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  32 in total

1.  Measuring insulin-stimulated phosphatidyl-inositol 3-kinase activity.

Authors:  Li-Ping Wang; Scott A Summers
Journal:  Methods Mol Med       Date:  2003

2.  Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways.

Authors:  Naoto Kubota; Yasuo Terauchi; Tetsuya Kubota; Hiroki Kumagai; Shinsuke Itoh; Hidemi Satoh; Wataru Yano; Hitomi Ogata; Kumpei Tokuyama; Iseki Takamoto; Tomoka Mineyama; Michiro Ishikawa; Masao Moroi; Kaoru Sugi; Toshimasa Yamauchi; Kohjiro Ueki; Kazuyuki Tobe; Tetsuo Noda; Ryozo Nagai; Takashi Kadowaki
Journal:  J Biol Chem       Date:  2006-01-23       Impact factor: 5.157

3.  The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21.

Authors:  Alexei Kharitonenkov; Victor J Wroblewski; Anja Koester; Yun-Fei Chen; Cathleen K Clutinger; Xenia T Tigno; Barbara C Hansen; Armen B Shanafelt; Garret J Etgen
Journal:  Endocrinology       Date:  2006-10-26       Impact factor: 4.736

4.  Endogenous glucose production is inhibited by the adipose-derived protein Acrp30.

Authors:  T P Combs; A H Berg; S Obici; P E Scherer; L Rossetti
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

5.  FGF21 reloaded: challenges of a rapidly growing field.

Authors:  Alexei Kharitonenkov; Philip Larsen
Journal:  Trends Endocrinol Metab       Date:  2010-12-29       Impact factor: 12.015

6.  Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states.

Authors:  Michael K Badman; Pavlos Pissios; Adam R Kennedy; George Koukos; Jeffrey S Flier; Eleftheria Maratos-Flier
Journal:  Cell Metab       Date:  2007-06       Impact factor: 27.287

7.  Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones.

Authors:  Paul A Dutchak; Takeshi Katafuchi; Angie L Bookout; Jang Hyun Choi; Ruth T Yu; David J Mangelsdorf; Steven A Kliewer
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

8.  FGF21 requires βklotho to act in vivo.

Authors:  Andrew C Adams; Christine C Cheng; Tamer Coskun; Alexei Kharitonenkov
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

9.  Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance.

Authors:  Jacob M Haus; Sangeeta R Kashyap; Takhar Kasumov; Renliang Zhang; Karen R Kelly; Ralph A Defronzo; John P Kirwan
Journal:  Diabetes       Date:  2008-11-13       Impact factor: 9.461

10.  βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism.

Authors:  Xunshan Ding; Jamie Boney-Montoya; Bryn M Owen; Angie L Bookout; Katie Colbert Coate; David J Mangelsdorf; Steven A Kliewer
Journal:  Cell Metab       Date:  2012-09-05       Impact factor: 27.287

View more
  223 in total

Review 1.  Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.

Authors:  Chiara Degirolamo; Carlo Sabbà; Antonio Moschetta
Journal:  Nat Rev Drug Discov       Date:  2015-11-16       Impact factor: 84.694

2.  The hepatokine FGF21 is crucial for peroxisome proliferator-activated receptor-α agonist-induced amelioration of metabolic disorders in obese mice.

Authors:  Tsuyoshi Goto; Mariko Hirata; Yumeko Aoki; Mari Iwase; Haruya Takahashi; Minji Kim; Yongjia Li; Huei-Fen Jheng; Wataru Nomura; Nobuyuki Takahashi; Chu-Sook Kim; Rina Yu; Shigeto Seno; Hideo Matsuda; Megumi Aizawa-Abe; Ken Ebihara; Nobuyuki Itoh; Teruo Kawada
Journal:  J Biol Chem       Date:  2017-04-12       Impact factor: 5.157

3.  Metabolism: Adiponectin---a mediator of specific metabolic actions of FGF21.

Authors:  Regina Goetz
Journal:  Nat Rev Endocrinol       Date:  2013-07-16       Impact factor: 43.330

4.  Fibroblast growth factor 21 increases hepatic oxidative capacity but not physical activity or energy expenditure in hepatic peroxisome proliferator-activated receptor γ coactivator-1α-deficient mice.

Authors:  Justin A Fletcher; Melissa A Linden; Ryan D Sheldon; Grace M Meers; E Matthew Morris; Anthony Butterfield; James W Perfield; R Scott Rector; John P Thyfault
Journal:  Exp Physiol       Date:  2018-01-16       Impact factor: 2.969

Review 5.  Adiponectin as a tissue regenerating hormone: more than a metabolic function.

Authors:  Tania Fiaschi; Francesca Magherini; Tania Gamberi; Pietro Amedeo Modesti; Alessandra Modesti
Journal:  Cell Mol Life Sci       Date:  2013-12-10       Impact factor: 9.261

Review 6.  Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis.

Authors:  Lucas D BonDurant; Matthew J Potthoff
Journal:  Annu Rev Nutr       Date:  2018-05-04       Impact factor: 11.848

Review 7.  The role of ceramides in metabolic disorders: when size and localization matters.

Authors:  Sarah M Turpin-Nolan; Jens C Brüning
Journal:  Nat Rev Endocrinol       Date:  2020-02-14       Impact factor: 43.330

8.  Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones.

Authors:  Andrew C Adams; Tamer Coskun; Christine C Cheng; Libbey S O Farrell; Susan L Dubois; Alexei Kharitonenkov
Journal:  Mol Metab       Date:  2013-05-29       Impact factor: 7.422

Review 9.  Curcumin and dietary polyphenol research: beyond drug discovery.

Authors:  Tian-Ru Jin
Journal:  Acta Pharmacol Sin       Date:  2018-03-15       Impact factor: 6.150

10.  Dietary Methionine Restriction Signals to the Brain Through Fibroblast Growth Factor 21 to Regulate Energy Balance and Remodeling of Adipose Tissue.

Authors:  Laura A Forney; Han Fang; Landon C Sims; Kirsten P Stone; Leighann Y Vincik; Alicia M Vick; Amanda N Gibson; David H Burk; Thomas W Gettys
Journal:  Obesity (Silver Spring)       Date:  2020-10       Impact factor: 5.002

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.